Flow cytometric detection of apoptotic bone marrow cells with fractional DNA content after application of WR-2721, cyclophosphamide, cisplatin, and exposure of mice to gamma rays

Human and Experimental Toxicology

Volumn 21, Issue 6, 2002, Pages 335-341

  Mazur, L ^a   Czyzewska, A ^a   Bochenek, M ^b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b NATIONAL RESEARCH INSTITUTE OF ANIMAL PRODUCTION   (Poland)

Author keywords

Apoptosis; Bone marrow cells; Cell cycle; Cisplatin; Cyclophosphamide; DNA degradation; Flow cytometry; Gamma rays; WR 2721

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; CISPLATIN; COBALT 60; CYCLOPHOSPHAMIDE; DNA; ALKYLATING AGENT; RADIOPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CELL ASSAY; CELL CYCLE; CELL PROTECTION; CONTROLLED STUDY; DNA DAMAGE; DNA DEGRADATION; FLOW CYTOMETRY; FREQUENCY ANALYSIS; GAMMA RADIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIATION PROTECTION; ANIMAL; DRUG EFFECT; PATHOLOGY;

AMIFOSTINE; ANIMAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BONE MARROW CELLS; CELL CYCLE; CISPLATIN; CYCLOPHOSPHAMIDE; DNA DAMAGE; FLOW CYTOMETRY; GAMMA RAYS; MALE; MICE; RADIATION-PROTECTIVE AGENTS; SUPPORT, NON-U.S. GOV'T; ANIMALS;

ANIMALIA;

EID: 0036591619     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/0960327102ht261oa     Document Type: Article

References (73)

1. Reducing the toxicity of anticancer therapy: New strategies
2. Normal tissue protection in cancer therapy progress and prospects
3. Chemoprotection in anticancer therapy: The emerging role of Amifostine (WR-2721)
4. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by Amifostine
5. The potential of Amifostine: From cytoprotectant to therapeutic agent
6. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects
7. The potential of Amifostine: From cytoprotectant to therapeutic agent
8. Modulation of radiation-induced apoptosis by thiolamines
9. In vivo Amifostine (WR-2721) prevents chemotherapy-induced apoptosis of peripheral blood lymphocytes from cancer patients Life
10. Immunocytochemical analysis of apoptotic bone marrow cells after treatment of mice with WR-2721 and chemotherapeutic drugs
11. Chemotherapy-induced apoptosis
12. Activation of apoptosis pathways by anticancer treatment
13. Induction of apoptosis by cancer chemotherapy
14. Apoptosis and cancer chemotherapy
15. Radiation-induced apoptosis: Relevance to radiotherapy
16. Radiation induced apoptosis
17. The molecular regulation of apoptosis and implications for radiation oncology
18. Radiation-induced apoptosis
19. Radiation-induced apoptosis
20. Apoptosis and programmed cell death in health and disease
21. Apoptosis: An overview
22. Molecular regulation of apoptosis
23. Apoptosis
24. Apoptoza w ukladzie hemopoetycznym
25. Apoptoza w ukladzie bialokrwinkowym
26. Multi-step chromatin degradation in apoptosis
27. The role of DNA fragmentation in apoptosis
28. Apoptotic DNA fragmentation
29. Morphologic and biochemical hallmarks of apoptosis
30. Flow cytometric analysis of cell death: A critical review
31. Methods in analysis of apoptosis and cell necrosis
32. Cytometry in cell necrobiology: Analysis of apoptosis and accidental cell death (Necrosis)
33. Assays of cell viability: Discrimination of cells dying by apoptosis
34. Measurement of apoptosis
35. Use of flow and laserscanning cytometry in analysis of cell death
36. Ionizing radiation damage to DNA: Molecular aspects
37. DNA damage and repair following treatment with ionizing radiation
38. The role of DNA single- and double-strand breaks in cell killing by ionizing radiation
39. The clinical use of mutagenic anticancer drugs
40. Genetic activity profiles of anticancer drugs
41. The early history of the biological alkylating agents
42. Cyclophosphamide toxicity
43. Clinical pharmacokinetics of cyclophosphamide
44. The molecular effects of acrolein
45. How does cisplatin alter DNA structure? A molecular mechanics study on double-stranded oligonucleotides
46. Interaction of platinum antitumor compounds
47. Solution structure of a cisplatin-induced DNA interstrand crosslink
48. Programmed cellular response to ionizing radiation damage
49. Role of nucleases in apoptosis
50. Enzymatic programming of apoptotic cell death
51. New aspects of the mechanism of DNA fragmentation in apoptosis
52. DNases and apoptosis
53. Review: Nuclear event in apoptosis
54. The molecular basis for cell cycle delays following ionizing radiation: A review
55. Effects of ionizing radiation on cell cycle progression
56. The cell cycle as therapeutic target
57. Cell cycle regulation in response to DNA damage in mammalian cells: A historical perspective
58. 2 phase of the cell cycle
59. Cell cycle and apoptosis: Common pathways to life and death
60. Apoptosis and the cell cycle
61. Exploration of platinum-based dose-intensive chemotherapy strategies with Amifostine (Ethyol)
62. Pharmacokinetics of cisplatin with and without Amifostine in tumor-bearing nude mice
63. Effects of GSH and WR-2721 on induction of micronuclei by cyclophosphamide
64. WR-2721: Inhibitor of cisplatin-induced micronuclei
65. Radioprotective action of aminothiols in vitro and in vivo: Comparison between effects on DNA damage and cell survival
66. Radioprotective effect of combinations of WR-2721 and mercaptopropionylglycine on mouse bone marrow chromosomes
67. Radioprotective effects of the thiols GSH and WR-2721 against X-ray-induction of micronuclei in erythroblasts
68. Accumulation of CHO cells in G2 phase following exposure to WR-1065
69. The effect of chemical radiation protectors on cell cycle progression after gamma or neutron irradiation
70. Chemical protection and the cell-cycle effects on radiation-induced mutagenesis
71. Effects of WR-2721 (Amifostine) and its metabolite WR-1065 on the antiproliferate activity of chemotherapeutic agents on neuroblastoma cells in vitro
72. Pharmacokinetics of WR-2721
73. Pharmacokinetics profile of Amifostine